Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Basilea Focuses on Commercialization

17 Dec 2007 - Basilea Pharmaceutica Ltd. announced a new management structure reflecting the company's high priority on commercializing its pre-registrations drugs.
 
Basilea has two investigatory drugs for high medical need currently undergoing regulatory review and a third compound in phase III testing. In anticipation of two potential product launches in the next 12 months, Basilea's Board of Directors has implemented a more focused management structure to optimally support the company's commercialization efforts.
 
"Successful commercialization of our innovative molecules is key to our future success. In order to achieve our goal we have restructured the management team to focus on this objective. We intend to fully focus and align our organization to build a profitable and sustainable business", commented Basilea Pharmaceutica CEO, Anthony Man.
 
The management committee, headed by Dr. Man, will consist of a representative from the following functions: Commercial Operations, Finance, Technical Operations/Supply Chain plus Development and Research. There are no changes in personnel involved in the new structure.